Glaxo holds secret talks with Human Genome Sciences GlaxoSmithKline made a $13-a-share offer for Human Genome Sciences (HGS) in April, which was turned down as it did not "reflect the value" of the business, despite being an 80pc premium on the last closing price of the stock. HGS, which is based in the US, began a search for a higher bidder and tomorrow is the deadline for new offers. As the deadline approaches and a rival bid looks increasingly unlikely the two firms are holding secret negotiations, reports The Sunday Times this morning. The two companies each own a 50pc share of Benlysta, a lupus drug, which is a potential blockbuster source of revenue.